Home

Upstream Bio, Inc. - Common Stock (UPB)

10.77
-0.23 (-2.09%)

Upstream Bio, Inc. is a biotechnology company focused on developing innovative therapies for patients with severe allergic diseases and other immune-mediated conditions

The company utilizes its expertise in biologics and immunology to design and advance treatments that target underlying disease mechanisms. Upstream Bio aims to address unmet medical needs with the potential for transformative solutions, working through rigorous research and clinical trials to bring new options to the healthcare market. Their commitment to improving patient outcomes drives their research and development efforts, as they seek to enhance the quality of life for individuals suffering from these challenging conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
Via MarketBeat · November 6, 2024
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Saybenzinga.com
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.
Via Benzinga · November 5, 2024
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · November 5, 2024
Another Trio Of Biotech IPOs Made Friday Debuttalkmarkets.com
The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and Camp4 Therapeutics each made their public debut.
Via Talk Markets · October 13, 2024